Your browser is no longer supported. Please, upgrade your browser.
Settings
CELG Celgene Corporation daily Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E25.69 EPS (ttm)4.25 Insider Own0.20% Shs Outstand783.03M Perf Week6.32%
Market Cap85.38B Forward P/E12.50 EPS next Y8.72 Insider Trans-15.02% Shs Float783.03M Perf Month6.55%
Income3.45B PEG1.27 EPS next Q1.92 Inst Own82.40% Short Float1.57% Perf Quarter-22.81%
Sales12.50B P/S6.83 EPS this Y28.10% Inst Trans1.56% Short Ratio1.67 Perf Half Y-9.91%
Book/sh12.56 P/B8.68 EPS next Y19.10% ROA13.30% Target Price123.97 Perf Year-3.69%
Cash/sh15.02 P/C7.26 EPS next 5Y20.21% ROE48.70% 52W Range94.55 - 147.17 Perf YTD-5.80%
Dividend- P/FCF20.47 EPS past 5Y11.80% ROI11.70% 52W High-25.91% Beta1.77
Dividend %- Quick Ratio3.50 Sales past 5Y18.30% Gross Margin96.40% 52W Low15.32% ATR2.61
Employees7132 Current Ratio3.70 Sales Q/Q10.20% Oper. Margin36.50% RSI (14)52.93 Volatility2.39% 2.33%
OptionableYes Debt/Eq0.77 EPS Q/Q466.70% Profit Margin31.70% Rel Volume0.70 Prev Close108.00
ShortableYes LT Debt/Eq0.67 EarningsJan 25 BMO Payout0.00% Avg Volume7.37M Price109.04
Recom2.10 SMA205.73% SMA50-4.61% SMA200-12.76% Volume5,143,890 Change0.96%
Dec-08-17Upgrade Atlantic Equities Neutral → Overweight
Oct-27-17Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-27-17Reiterated SunTrust Buy $156 → $127
Oct-27-17Reiterated Barclays Equal Weight $135 → $105
Oct-27-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-26-17Downgrade Wells Fargo Outperform → Market Perform
Oct-24-17Initiated Guggenheim Buy $160
Oct-23-17Resumed Piper Jaffray Neutral $133
Oct-20-17Reiterated UBS Buy $153 → $146
Oct-20-17Downgrade Robert W. Baird Outperform → Neutral $162 → $136
Oct-20-17Downgrade Citigroup Buy → Neutral
Oct-17-17Initiated Bernstein Outperform
Oct-05-17Downgrade Morgan Stanley Equal-Weight → Underweight
Sep-15-17Reiterated Mizuho Buy $134 → $158
Sep-15-17Initiated RBC Capital Mkts Top Pick $176
Jul-31-17Upgrade Argus Hold → Buy
Jul-28-17Resumed Stifel Buy $155
Jul-11-17Resumed Jefferies Buy
Jun-30-17Downgrade BTIG Research Buy → Neutral
Jun-16-17Upgrade Leerink Partners Mkt Perform → Outperform
Dec-12-17 05:52PM  Juno Reports Additional Data on CAR-T Therapy, Shares Drop Zacks
09:55AM  Bluebird's Shares Jump on Strong Data for CAR-T Therapy Zacks
07:14AM  ASH 2017: CAR-T Wallops Blood Cancer Motley Fool
Dec-11-17 07:13PM  Bluebird Bio Stock Soars After Company Details Promising Cancer Treatment TheStreet.com
06:01PM  Now, That's Why You Buy Biotech Stocks! Bluebird Soars 18% Barrons.com
05:35PM  Amgen's Kyprolis improves overall survival in blood cancer patients Reuters
05:00PM  4 Stocks Move to Start the Week GuruFocus.com
04:31PM  Biotech Stocks Soar On Trial Data At Hematology Conference Investor's Business Daily
04:24PM  11 Biotech Stocks Moving From ASH 2017 Benzinga
01:48PM  Celgene CEO: New therapies for a certain type of cancer boost survival rates 10-fold CNBC
12:06PM  Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today Zacks
10:24AM  Celgene's Lymphoma Strategy Is Its Biggest Positive, Analyst Says Benzinga
09:19AM  After Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target Benzinga
09:15AM  bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results Motley Fool
09:07AM  The Zacks Analyst Blog Highlights: Bank of America, Celgene, Goldman Sachs, L Brands and Quest Diagnostics Zacks
09:05AM  Highlights from ASH Sent bluebird Bio Inc (BLUE) Shares Skyrocketing; J.P. Morgan Cheers SmarterAnalyst
07:02AM  Celgene takes new approach to multiple myeloma treatment CNBC Videos
07:00AM  Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Business Wire
Dec-10-17 04:45PM  Top 3 Healthcare Stocks for 2017 Investopedia
10:30AM  Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting Business Wire
10:30AM  Bluebird, Celgene Myeloma Therapy Appears to Improve in Time Bloomberg
Dec-08-17 04:00PM  3 Growth Stocks for the Long Term Motley Fool
03:28PM  Top Research Reports for Bank of America, Celgene & Goldman Sachs Zacks
01:40PM  Putting Your Money into Infrastructure CNBC Videos
09:57AM  Why Biotech Stocks May Wait A While Before Feeling The Love Investor's Business Daily
09:29AM  Sanofi Begins Combo Studies on Multiple Myeloma Candidate Zacks
09:01AM  Morning Movers: United, Celgene Climb; Ciena Slips Barrons.com
08:04AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Dec-07-17 01:13PM  ETFs with exposure to Celgene Corp. : December 7, 2017 Capital Cube
11:45AM  Long-Term Efficacy Data from the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated with ABRAXANE® Vs. Solvent-Based Paclitaxel to Be Reported Business Wire
10:45AM  CKPT: A Mad Scramble for Combination Therapy Makes Checkpoint a Gem Zacks Small Cap Research
07:31AM  Here's Why bluebird bio's Shares Soared 24% in November Motley Fool
Dec-06-17 04:50PM  Top 5 Biotech Stocks for 2017 Investopedia
02:20PM  CKPT: A Smokin Opportunity in PD-L1 Therapy and Beyond Zacks Small Cap Research
Dec-05-17 07:30AM  What Analysts Recommend for Pfizer in November 2017 Market Realist
07:30AM  Celgene Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Capacity Building in Resource-Constrained Countries Business Wire
Dec-04-17 08:32AM  3 Reasons Pfizer Should Buy Celgene in 2018 Motley Fool
08:05AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Dec-03-17 09:09AM  5 Top Biotech Stocks to Buy Now Motley Fool
Dec-01-17 08:42AM  3 Biotech Stocks to Buy in December Motley Fool
08:03AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Nov-30-17 08:02AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Nov-29-17 07:29PM  Forget Penny Stocks, Your Money Is Better Off in These 3 Companies Motley Fool
07:37AM  What Should Investors Know About The Future Of Celgene Corporations (CELG) Business? Simply Wall St.
Nov-28-17 07:02PM  Cramer's lightning round: Don't be greedy, buy Celgene he... CNBC Videos
06:50PM  Cramer's lightning round: Don't be greedy, buy Celgene here CNBC
08:00AM  Analysis: Positioning to Benefit within Kirby, AmerisourceBergen, Celgene, Sabre, Noble Energy, and Idera Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
02:20AM  Why Is Celgene (CELG) Up 3.4% Since the Last Earnings Report? Zacks
Nov-27-17 12:38PM  ETFs with exposure to Celgene Corp. : November 27, 2017 Capital Cube
12:23PM  Biotechs Celgene, Biogen May Rally Through Yearend Investopedia
11:32AM  U.S. Supreme Court divided over legality of patent reviews Reuters
Nov-24-17 01:06PM  CAR-T Therapy Space 2017 Progress Report Zacks
Nov-21-17 08:00AM  Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American Society of Hematology Annual Meeting (ASH) Business Wire
07:30AM  Celgene Corporation to Webcast an Analyst and Investor Event from the American Society of Hematology Meeting in December Business Wire
Nov-20-17 01:55PM  Celgene Corporation Stock Is a Steal Right Now, Heres Why InvestorPlace
08:04AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
06:00AM  The Market Tells a Tale of Two Gaps TheStreet.com
Nov-17-17 09:24AM  Biotech Funds Flashing Sell Signals Investopedia
08:30AM  Can This Tiny Biotech Stock Pay Off Big for Celgene? Motley Fool
07:22AM  Trade of the Day: Celgene Corporation Attempts a Breakout InvestorPlace
07:09AM  Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3 Zacks
Nov-16-17 05:43PM  Biotech Industry: Small Innovators Outflank Big Caps As Blockbuster Drug Patent Cliff Looms Investor's Business Daily
08:30AM  Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma Business Wire
Nov-15-17 08:17PM  3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock Motley Fool
08:06AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Nov-14-17 03:03PM  7 Life Science Stocks to Buy Today InvestorPlace
02:08PM  Why Biotech Stocks Are Nearing a Rebound Investopedia
08:02AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Nov-13-17 11:58AM  ETFs with exposure to Celgene Corp. : November 13, 2017 Capital Cube
10:16AM  A Rare Quarterly Appearance by bluebird bio Inc.'s Management Motley Fool
09:31AM  3 Top Healthcare Stocks to Buy in November Motley Fool
07:00AM  Mixed Prognosis for Healthcare Stocks InvestorPlace
Nov-12-17 09:09AM  5 Irresistible Reasons to Buy Celgene Stock Right Now (Hint: 1 Is that It's Dirt Cheap) Motley Fool
08:00AM  3 Top Biotech Stocks for 2018 Motley Fool
Nov-10-17 03:02PM  Why Immunomedics, Inc. Jumped Higher Today Motley Fool
11:35AM  What Investors Should Know About Celgene Corporations (CELG) Financial Strength Simply Wall St.
10:40AM  Short Sellers Grow More Selective on Major Biotechs 24/7 Wall St.
Nov-09-17 07:16PM  Cramer's lightning round: You don't want to touch Pandora... CNBC Videos
02:53PM  Biotech Celgene Could Rebound By More Than 15% Investopedia
02:38PM  Top 3 Healthcare Stocks for 2017 Investopedia
09:01AM  Analysts Recommendations for Celgene in November 2017 Market Realist
07:34AM  5 Top Stocks for November Motley Fool
07:32AM  How Celgenes Abraxane Is Positioned after 3Q17 Market Realist
Nov-08-17 03:45PM  How Celgenes Otezla Is Positioned after 3Q17 Market Realist
02:55PM  Wall Street dealmaking is heating up, but it's not a sign stocks are topping: NYSE trader Yahoo Finance Video
02:15PM  How Celgenes Revlimid and Pomalyst Are Positioned after 3Q17 Market Realist
01:31PM  How to Invest in Biotech Stocks Motley Fool
12:41PM  How Did Celgene Perform in 3Q17? Market Realist
09:35AM  5 Technical Levels Discussed On Wednesday's PreMarket Prep Benzinga
Nov-07-17 07:07PM  Cramer's lightning round: Don't give up on Incyte CNBC Videos
07:00PM  Why Inovio Pharmaceuticals Stock Sank in October Motley Fool
06:56AM  The Zacks Analyst Blog Highlights: Facebook, Celgene, BlackRock, Danaher and BP Zacks
06:02AM  The Only 3 Big Pharma Companies Growing Market Share Motley Fool
Nov-06-17 04:37PM  Top Stock Reports for Facebook, Celgene & BlackRock Zacks
03:25PM  Top 5 Biotech Stocks for 2017 Investopedia
10:59AM  Only a handful of stocks are driving the stock market rallyagain Yahoo Finance Video
Nov-03-17 05:18PM  Why Celgene Crashed 30% in October -- and What Now? Motley Fool
12:02PM  ETFs with exposure to Celgene Corp. : November 3, 2017 Capital Cube
08:34AM  3 Reasons It's Smart to Buy Celgene's Stock Now Motley Fool
Nov-02-17 04:13PM  Buy Bad News in Celgene, General Electric, Under Armour TheStreet.com
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. and Nimbus Therapeutics. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAPLAN GILLADirectorDec 05Option Exercise24.979,250230,92685,551Dec 06 04:45 PM
MARIO ERNESTDirectorOct 30Option Exercise31.8013,600432,41271,024Nov 01 04:11 PM
KELLOGG PETER NSee RemarksOct 27Option Exercise0.002,100041,823Oct 31 04:10 PM
HUGIN ROBERT Jsee remarksOct 26Option Exercise31.8162,0201,972,5501,060,106Oct 26 04:44 PM
Curran TerrieSee remarksSep 25Sale143.891,727248,4983,925Sep 26 04:29 PM
KAPLAN GILLADirectorSep 12Option Exercise33.889,250313,39085,551Sep 14 04:35 PM
KAPLAN GILLADirectorSep 12Sale141.569,2501,309,43076,301Sep 14 04:35 PM
CASEY MICHAEL DDirectorSep 05Sale139.039,2501,286,0280Sep 06 06:53 PM
MARIO ERNESTDirectorAug 10Sale130.5218,5062,415,40369,424Aug 14 04:53 PM
KAPLAN GILLADirectorAug 02Sale134.527,5001,008,90076,301Aug 03 04:45 PM
Curran TerrieSee remarksAug 01Option Exercise0.001,50006,210Aug 02 04:38 PM
KELLOGG PETER NSee RemarksAug 01Option Exercise0.0060,000070,833Aug 02 04:37 PM
Smith Scott AndrewSee RemarksJul 28Option Exercise0.005,000045,415Aug 01 05:34 PM
PEHL MICHAEL F.See remarksJul 28Option Exercise0.002,50003,488Aug 01 04:56 PM
HUGIN ROBERT Jsee remarksJul 28Option Exercise0.0044,50001,021,159Aug 01 04:52 PM
Alles Mark JSee RemarksJul 28Option Exercise0.004,2000175,120Aug 01 04:48 PM
MARIO ERNESTDirectorJul 01Option Exercise0.00734087,930Jul 05 07:33 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00734024,361Jul 05 07:33 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073400Jul 05 07:31 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00734083,801Jul 05 07:32 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073400Jul 05 07:30 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00734023,880Jul 05 07:31 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00734012,066Jul 05 07:29 PM
LOUGHLIN JAMES JDirectorJun 26Option Exercise29.4318,500544,36332,877Jun 27 04:39 PM
LOUGHLIN JAMES JDirectorJun 26Sale133.5718,5002,471,04523,627Jun 27 04:39 PM
Friedman Michael ADirectorJun 22Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Option Exercise29.49178,7205,271,0061,033,909Jun 23 04:02 PM
HUGIN ROBERT Jsee remarksJun 22Sale134.14175,97023,604,616973,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 22Sale135.005,000675,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Option Exercise33.889,250313,3909,250Jun 23 04:05 PM
Friedman Michael ADirectorJun 21Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 21Sale130.005,000650,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Sale133.059,2501,230,7130Jun 23 04:05 PM
Friedman Michael ADirectorJun 19Option Exercise59.065,000295,3000Jun 20 04:07 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00333087,196Jun 20 04:09 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00333023,627Jun 20 04:08 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333083,067Jun 20 04:08 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
VESSEY RUPERTSee remarksJun 15Option Exercise104.164,007417,3584,785Jun 16 04:11 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375086,863Jun 16 04:11 PM
KAPLAN GILLADirectorJun 15Option Exercise0.00375082,734Jun 16 04:09 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.00375023,294Jun 16 04:10 PM
Haller Julia ADirectorJun 15Option Exercise0.003750575Jun 16 04:09 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 16 04:08 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.003750375Jun 16 04:06 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 16 04:06 PM
VESSEY RUPERTSee remarksJun 15Sale120.184,785575,0380Jun 16 04:11 PM
KAPLAN GILLADirectorJun 01Option Exercise28.979,250267,92682,359Jun 02 04:11 PM
CASEY MICHAEL DDirectorMay 30Option Exercise28.979,250267,926100,612May 31 04:10 PM
LOUGHLIN JAMES JDirectorMay 01Option Exercise28.969,250267,88032,169May 02 04:20 PM
LOUGHLIN JAMES JDirectorMay 01Sale124.009,2501,147,00022,919May 02 04:20 PM
HUGIN ROBERT Jsee remarksApr 10Option Exercise29.0260,0001,741,200973,909Apr 12 04:24 PM
KAPLAN GILLADirectorMar 30Sale123.8314,0331,737,70673,109Mar 31 05:31 PM
KAPLAN GILLADirectorMar 03Option Exercise25.587,500191,81387,142Mar 07 04:37 PM
VESSEY RUPERTSee remarksMar 01Sale124.424,000497,672778Mar 02 04:04 PM
CASEY MICHAEL DDirectorFeb 27Option Exercise25.587,500191,8507,500Mar 01 04:15 PM
CASEY MICHAEL DDirectorFeb 27Sale121.557,500911,6250Mar 01 04:15 PM
MARIO ERNESTDirectorFeb 27Sale121.2412,0001,454,88057,424Aug 31 04:03 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62306,773Feb 06 04:14 PM
Celgene Switzerland LLC10% OwnerFeb 01Buy16.00625,00010,000,0003,456,463Feb 01 04:18 PM
HUGIN ROBERT Jsee remarksJan 05Option Exercise27.4322,708622,767913,909Jan 09 04:11 PM
Smith Scott AndrewSee RemarksDec 23Option Exercise0.006,400039,875Dec 27 04:17 PM